Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Rebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
When a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Leading West Michigan practice now affiliated with nation’s largest urological healthcare management company
Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Here are seven ways texting can improve healthcare revenue and decrease costs.
"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Independent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.
"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Multiple investigational agents have been developed and are being studied.
"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.
Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.